Abstract
Large international efforts are describing how germline variants influence susceptibility to lung cancer. We have undertaken a genome-wide association by proxy (GWAx) study of lung cancer in 48,843 proxy “cases” with a parent/sibling with lung cancer to 195,387 proxy controls without a family history of any cancer from the UK Biobank and meta-analysed the results with previously described GWA study results. 21 loci achieved genome-wide statistical significance, including 8 novel loci including expression quantitative trait loci (eQTLs) in DNA repair genes (CHEK1, MDM4) and metabolic genes (CYP1A1). This study also discovered loci associated with propensity to smoke, such as both subunits of a key element in nicotine response, the neuronal α4β2 nicotinic acetylcholine receptor. Polygenic risk scores (PRS) analysis of variants below genome-wide significant threshold in an independent lung cancer population demonstrated that variants related to eQTLs and/or smoking propensity are enriched for susceptibility variants. PRS of lung cancer variants related to propensity to smoke were associated with somatic mutation burden in matched tumours from the same patients, with individuals with higher polygenic genetic risk having increased mutation burden in two case cohorts. This study has expanded the number of susceptibility loci linked with lung cancer and provided insights into how the molecular mechanisms by which these susceptibility variants contribute to the development of lung cancer.
Tags Lung Cancer, GWAx, GWAS, Smoking, Cancer, CHRNA4, CHRNB2, Mutational Burden, CHEK1, MDM4, CYP1A1, α4β2 nicotinic acetylcholine receptor, Mutational Signatures, RP11-10O17.1
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Institut National du Cancer (INCa) (GeniLuc 2017-1-TABAC-03-CIRC-1 - [TABAC 17 022], NIH/NCI, Integral NIH 5U19CA203654-03, Cancer Research UK [grant number C18281/A29019], the France Genomique National infrastructure, funded as part of the Investissements d'Avenir program managed by the Agence Nationale pour la Recherche (contract ANR-10-INBS-09). Christopher Amos is a Research Scholar of the Cancer Prevention Institute of Texas and supported by RR170048.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study contains a meta-analysis from already published data. The lung cancer cohort in McKay 2017 and the UK Biobank in Bycroft 2018. In the replication cohort for the somatic PRS, the GeniLuc cohort has not previously been publish. Ethnics for the GeniLuc cohort was reviewed by the IARC ethnics board (IARC IRB 12-05) and approved on 28th of April 2016.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available on request